Patents by Inventor Jacqueline Wyatt

Jacqueline Wyatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of casein kinase 2-alpha expression
    Publication number: 20020147163
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Casein kinase 2-alpha. Methods of using these compounds for modulation of Casein kinase 2-alpha expression and for treatment of diseases associated with expression of Casein kinase 2-alpha are provided.
    Type: Application
    Filed: February 8, 2001
    Publication date: October 10, 2002
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Susan M. Freier, Jacqueline Wyatt
  • Antisense modulation of phosphorylase kinase Alpha 2 expression
    Patent number: 6458591
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phosphorylase kinase alpha 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phosphorylase kinase alpha 2. Methods of using these compounds for modulation of Phosphorylase kinase alpha 2 expression and for treatment of diseases associated with expression of Phosphorylase kinase alpha 2 are provided.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: October 1, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Jacqueline Wyatt
  • Antisense modulation of casein kinase 2-alpha prime expression
    Patent number: 6455307
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-alpha prime. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Casein kinase 2-alpha prime. Methods of using these compounds for modulation of Casein kinase 2-alpha prime expression and for treatment of diseases associated with expression of Casein kinase 2-alpha prime are provided.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: September 24, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Robert McKay, Susan M. Freier, Jacqueline Wyatt
  • Antinsense modulation of Her-1 expression
    Patent number: 6444465
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human Her-1. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding Her-1. Methods of using these oligonucleotides for inhibition of Her-1 expression and for treatment of diseases such as cancers associated with overexpression of Her-1 are provided.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: September 3, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Jacqueline Wyatt, Susan M. Freier
  • Antisense modulation of E2F transcription factor 2 expression
    Patent number: 6444464
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 2. Methods of using these compounds for modulation of E2F transcription factor 2 expression and for treatment of diseases associated with expression of E2F transcription factor 2 are provided.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: September 3, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Jacqueline Wyatt
  • Antisense modulation of casein kinase 2-beta expression
    Patent number: 6440738
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Casein kinase 2-beta. Methods of using these compounds for modulation of Casein kinase 2-beta expression and for treatment of diseases associated with expression of Casein kinase 2-beta are provided.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: August 27, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Jacqueline Wyatt
  • Antisense modulation of damage-specific DNA binding protein 1, p127 expression
    Publication number: 20020103146
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 1, p127. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 1, p127. Methods of using these compounds for modulation of Damage-specific DNA binding protein 1, p127 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 1, p127 are provided.
    Type: Application
    Filed: December 6, 2000
    Publication date: August 1, 2002
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt
  • Antisense modulation of phosphorylase kinase alpha 1 expression
    Patent number: 6426188
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phosphorylase kinase alpha 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phosphorylase kinase alpha 1. Methods of using these compounds for modulation of Phosphorylase kinase alpha 1 expression and for treatment of diseases associated with expression of Phosphorylase kinase alpha 1 are provided.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: July 30, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Jacqueline Wyatt
  • Antisense modulation of BH3 interacting domain death agonist expression
    Publication number: 20020082228
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of BH3 Interacting domain Death agonist. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BH3 Interacting domain Death agonist. Methods of using these compounds for modulation of BH3 Interacting domain Death agonist expression and for treatment of diseases associated with expression of BH3 Interacting domain Death agonist are provided.
    Type: Application
    Filed: March 7, 2001
    Publication date: June 27, 2002
    Inventors: Hong Zhang, Jacqueline Wyatt
  • Antisense inhibition of A20 expression
    Patent number: 6387699
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of A20. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding A20. Methods of using these compounds for modulation of A20 expression and for treatment of diseases associated with expression of A20 are provided.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: May 14, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Jacqueline Wyatt
  • Antisense modulation of PTP1B expression
    Publication number: 20020055479
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: May 14, 2001
    Publication date: May 9, 2002
    Inventors: Lex M. Cowsert, Jacqueline Wyatt, Susan M. Freier, Brett P. Monia, Madeline M. Butler, Robert McKay
  • Antisense modulation of damage-specific DNA binding protein 2, p48 expression
    Patent number: 6379960
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 2, p48. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 2, p48. Methods of using these compounds for modulation of Damage-specific DNA binding protein 2, p48 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 2, p48 are provided.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: April 30, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt
  • Alteration of cellular behavior by antisense modulation of mRNA processing
    Publication number: 20020049173
    Abstract: The present invention provides compositions and methods for controlling the behavior of a cell, tissue or organism through antisense modulation of mRNA processing, using antisense compounds which does not support cleavage of the mRNA target.
    Type: Application
    Filed: December 12, 2000
    Publication date: April 25, 2002
    Inventors: C. Frank Bennett, Stanley T. Crooke, Muthiah Manoharan, Jacqueline Wyatt, Brenda F. Baker, Brett P. Monia, Robert McKay, James G. Karras
  • Antisense modulation of inhibitor of DNA binding-1 expression
    Patent number: 6372433
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor of DNA binding-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor of DNA binding-1. Methods of using these compounds for modulation of Inhibitor of DNA binding-1 expression and for treatment of diseases associated with expression of Inhibitor of DNA binding-1 are provided.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: April 16, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, C. Frank Bennett, Jacqueline Wyatt
  • Antisense inhibition of Phosphorylase kinase beta expression
    Patent number: 6368856
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phosphorylase kinase beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phosphorylase kinase beta. Methods of using these compounds for modulation of Phosphorylase kinase beta expression and for treatment of diseases associated with expression of Phosphorylase kinase beta are provided.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: April 9, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of lysophospholipase I expression
    Patent number: 6365354
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Lysophospholipase I. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Lysophospholipase I. Methods of using these compounds for modulation of Lysophospholipase I expression and for treatment of diseases associated with expression of Lysophospholipase I are provided.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: April 2, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Jacqueline Wyatt
  • Antisense modulation of Fas mediated signaling
    Publication number: 20020004490
    Abstract: Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.
    Type: Application
    Filed: March 9, 2001
    Publication date: January 10, 2002
    Inventors: Nicholas M. Dean, Eric G. Marcusson, Jacqueline Wyatt, Hong Zhang
  • Antisense modulation of glioma-associated oncogene-1 expression
    Patent number: 6329203
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glioma-associated oncogene-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glioma-associated oncogene-1. Methods of using these compounds for modulation of glioma-associated oncogene-1 expression and for treatment of diseases associated with expression of glioma-associated oncogene-1 are provided.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: December 11, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Jacqueline Wyatt
  • Antisense modulation of glycogen synthase kinase 3 beta expression
    Patent number: 6323029
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: November 27, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Madeline M. Butler, Robert McKay, Brett P. Monia, Jacqueline Wyatt
  • Antisense inhibition of glycogen synthase kinase 3 alpha expression
    Patent number: 6316259
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 alpha. Methods of using these compounds for modulation of glycogen synthase kinase 3 alpha expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 alpha are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: November 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Robert McKay, Madeline M. Butler, Jacqueline Wyatt